Chiasma Announces Completion of $70 Million Series E Financing

NEWTON, Mass. and JERUSALEM, Feb. 27, 2015 -- (Healthcare Sales & Marketing Network) -- Chiasma, Inc., a U.S. privately-held biopharma company developing octreotide capsules, its lead product for the orphan condition acromegaly, today announced the closin... Biopharmaceuticals, Venture CapitalChiasma, octreotide capsules, acromegaly
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news